A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer.
Irlam, Joely J
Betts, Guy N J
Miller, Crispin J
West, Catharine M L
AffiliationTranslational Radiobiology Group, Institute of Cancer Sciences, University of Manchester, Christie Hospital, Manchester, United Kingdom.
MetadataShow full item record
AbstractTumor hypoxia is associated with a poor prognosis, hypoxia modification improves outcome, and hypoxic status predicts benefit from treatment. Yet, there is no universal measure of clinical hypoxia. The aim of this study was to investigate whether a 26-gene hypoxia signature predicted benefit from hypoxia-modifying treatment in both cancer types.
CitationA 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer. 2013, 19 (17):4879-88 Clin Cancer Res
JournalClinical Cancer Research
- A Gene Signature for Selecting Benefit from Hypoxia Modification of Radiotherapy for High-Risk Bladder Cancer Patients.
- Authors: Yang L, Taylor J, Eustace A, Irlam JJ, Denley H, Hoskin PJ, Alsner J, Buffa FM, Harris AL, Choudhury A, West CML
- Issue date: 2017 Aug 15
- Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial.
- Authors: Janssens GO, Rademakers SE, Terhaard CH, Doornaert PA, Bijl HP, van den Ende P, Chin A, Marres HA, de Bree R, van der Kogel AJ, Hoogsteen IJ, Bussink J, Span PN, Kaanders JH
- Issue date: 2012 May 20
- Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial.
- Authors: Eustace A, Irlam JJ, Taylor J, Denley H, Agrawal S, Choudhury A, Ryder D, Ord JJ, Harris AL, Rojas AM, Hoskin PJ, West CM
- Issue date: 2013 Jul
- Computed tomography-based tumour volume as a predictor of outcome in laryngeal cancer: results of the phase 3 ARCON trial.
- Authors: Janssens GO, van Bockel LW, Doornaert PA, Bijl HP, van den Ende P, de Jong MA, van den Broek GB, Verbist BM, Terhaard CH, Span PN, Kaanders JH
- Issue date: 2014 Apr
- Acute toxicity profile and compliance to accelerated radiotherapy plus carbogen and nicotinamide for clinical stage T2-4 laryngeal cancer: results of a phase III randomized trial.
- Authors: Janssens GO, Terhaard CH, Doornaert PA, Bijl HP, van den Ende P, Chin A, Pop LA, Kaanders JH
- Issue date: 2012 Feb 1